Aligos Therapeutics Inc
ALGS
Company Profile
Business description
Aligos Therapeutics Inc is a clinical stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others.
Contact
One Corporate Drive
2nd Floor
South San FranciscoCA94080
USAT: +1 800 466-6059
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
70
Stocks News & Analysis
stocks
Chart of the Week: We see opportunity in Mineral Resources despite debt concerns
Shares trade at a discount despite attractive longer-term outlook.
stocks
The ultimate investing hack: dividend growth stocks
Finding companies built for lasting dividend growth.
stocks
Is the data centre party over for Goodman?
Global spending spree on data centres could mean a declining return on invested capital.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,896.10 | 20.40 | -0.23% |
| CAC 40 | 8,087.42 | 12.81 | 0.16% |
| DAX 40 | 23,693.71 | 17.15 | -0.07% |
| Dow JONES (US) | 47,882.90 | 408.44 | 0.86% |
| FTSE 100 | 9,692.07 | 9.73 | -0.10% |
| HKSE | 25,804.90 | 44.17 | 0.17% |
| NASDAQ | 23,454.09 | 40.42 | 0.17% |
| Nikkei 225 | 50,596.24 | 731.56 | 1.47% |
| NZX 50 Index | 13,479.82 | 102.72 | -0.76% |
| S&P 500 | 6,849.72 | 20.35 | 0.30% |
| S&P/ASX 200 | 8,604.90 | 13.90 | -0.16% |
| SSE Composite Index | 3,876.41 | 1.59 | -0.04% |